Tax-related share sales by Kura Oncology (NASDAQ: KURA) CLO

Rhea-AI Filing Summary

Kura Oncology Chief Legal Officer Teresa Bair reported routine tax-related stock sales. On 01/27/2026, she sold 4,096, 2,335 and 4,777 shares of Kura Oncology common stock in three separate transactions, each at $8.4607 per share.

All three transactions were disclosed as sell-to-cover trades for taxes due on vesting restricted stock units granted on 02/16/23, 01/02/24 and 01/02/25. Following the last transaction, she directly beneficially owned 226,931 Kura Oncology shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bair Teresa Brophy

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/27/2026		S		4,096	D(1)	$8.4607	234,043	D
Common Stock	01/27/2026		S		2,335	D(2)	$8.4607	231,708	D
Common Stock	01/27/2026		S		4,777	D(3)	$8.4607	226,931	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25.

2. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23.

3. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24.

	Teresa Bair	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in this KURA Form 4 filing and what is their role?

The insider is Teresa Bair, who serves as Chief Legal Officer of Kura Oncology, Inc. The filing identifies her as an officer, not a director or 10% owner, and reports changes in her beneficial ownership of Kura Oncology common stock.

What did KURA’s Chief Legal Officer report in this Form 4 filing?

The filing reports that Teresa Bair sold multiple blocks of Kura Oncology common stock on January 27, 2026. The transactions are described as sell-to-cover sales related to tax obligations arising from the vesting of previously granted restricted stock units.

How many Kura Oncology (KURA) shares were sold in the reported transactions?

The Form 4 shows three separate sales of Kura Oncology common stock: 4,096 shares, 2,335 shares and 4,777 shares. Each transaction is coded as a sale and occurred on January 27, 2026 at the same reported share price.

At what price were the Kura Oncology (KURA) shares sold in this Form 4?

The reported sales of Kura Oncology common stock were executed at $8.4607 per share. All three sell-to-cover transactions on January 27, 2026 used this same price, as disclosed in the Form 4 transaction table.

Why did KURA’s Chief Legal Officer sell shares according to this Form 4?

The footnotes explain each transaction was a sell-to-cover for taxes tied to vesting restricted stock units. These RSUs were originally granted on 02/16/23, 01/02/24 and 01/02/25, and shares were sold to satisfy associated tax obligations.

How many Kura Oncology (KURA) shares does the insider own after these sales?

After the last reported transaction, the Form 4 shows 226,931 Kura Oncology common shares beneficially owned directly by Teresa Bair. This figure reflects her direct ownership position following the January 27, 2026 sell-to-cover sales.